 Jonathan Kaufman
Concepts (263)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units, Pediatric | 7 | 2020 | 189 | 1.810 |
Why?
| | Cardiac Surgical Procedures | 11 | 2020 | 501 | 1.770 |
Why?
| | Heart Defects, Congenital | 11 | 2020 | 752 | 1.530 |
Why?
| | Hyponatremia | 2 | 2016 | 40 | 0.950 |
Why?
| | Postoperative Complications | 9 | 2020 | 2494 | 0.930 |
Why?
| | Quality Improvement | 3 | 2018 | 1101 | 0.910 |
Why?
| | Enteral Nutrition | 7 | 2020 | 186 | 0.770 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2022 | 1570 | 0.670 |
Why?
| | Multiple Myeloma | 4 | 2022 | 120 | 0.670 |
Why?
| | Intensive Care Units | 5 | 2020 | 730 | 0.660 |
Why?
| | Airway Extubation | 1 | 2020 | 53 | 0.640 |
Why?
| | Infant, Newborn | 23 | 2020 | 5704 | 0.640 |
Why?
| | Vascular Access Devices | 1 | 2018 | 25 | 0.590 |
Why?
| | Cardiac Care Facilities | 1 | 2017 | 13 | 0.580 |
Why?
| | Postoperative Care | 3 | 2014 | 246 | 0.570 |
Why?
| | Hypernatremia | 1 | 2016 | 9 | 0.540 |
Why?
| | Heart Diseases | 3 | 2016 | 356 | 0.540 |
Why?
| | Hypoplastic Left Heart Syndrome | 2 | 2014 | 116 | 0.510 |
Why?
| | Vasodilator Agents | 3 | 2013 | 325 | 0.500 |
Why?
| | Stem Cell Transplantation | 2 | 2022 | 167 | 0.500 |
Why?
| | Boronic Acids | 3 | 2014 | 37 | 0.470 |
Why?
| | Tachycardia | 2 | 2014 | 54 | 0.460 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 48 | 0.450 |
Why?
| | Infant | 17 | 2020 | 8994 | 0.450 |
Why?
| | Blood Chemical Analysis | 1 | 2014 | 94 | 0.450 |
Why?
| | Infant, Premature | 3 | 2020 | 540 | 0.450 |
Why?
| | Pyrazines | 3 | 2014 | 88 | 0.440 |
Why?
| | Parenteral Nutrition | 1 | 2015 | 108 | 0.440 |
Why?
| | Milrinone | 1 | 2013 | 29 | 0.430 |
Why?
| | Norwood Procedures | 1 | 2013 | 29 | 0.430 |
Why?
| | Calcitonin | 1 | 2013 | 24 | 0.430 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2013 | 30 | 0.430 |
Why?
| | Prilocaine | 1 | 2013 | 4 | 0.420 |
Why?
| | Methemoglobinemia | 1 | 2013 | 13 | 0.420 |
Why?
| | Dexamethasone | 5 | 2022 | 330 | 0.420 |
Why?
| | Lidocaine | 1 | 2013 | 42 | 0.410 |
Why?
| | Critical Illness | 2 | 2016 | 753 | 0.410 |
Why?
| | Tidal Volume | 1 | 2013 | 83 | 0.410 |
Why?
| | Protein Precursors | 1 | 2013 | 126 | 0.410 |
Why?
| | Thrombosis | 2 | 2018 | 331 | 0.400 |
Why?
| | Masks | 1 | 2013 | 59 | 0.400 |
Why?
| | Nutritional Status | 1 | 2015 | 325 | 0.400 |
Why?
| | Anesthetics, Local | 1 | 2013 | 85 | 0.400 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2013 | 69 | 0.390 |
Why?
| | Bronchiolitis | 1 | 2013 | 92 | 0.390 |
Why?
| | Cardiac Output, Low | 1 | 2012 | 66 | 0.380 |
Why?
| | Cardiotonic Agents | 1 | 2012 | 128 | 0.370 |
Why?
| | Catheter Obstruction | 1 | 2011 | 4 | 0.370 |
Why?
| | Weight Gain | 1 | 2015 | 504 | 0.370 |
Why?
| | C-Reactive Protein | 1 | 2013 | 394 | 0.360 |
Why?
| | Chylothorax | 1 | 2010 | 13 | 0.360 |
Why?
| | Octreotide | 1 | 2010 | 26 | 0.350 |
Why?
| | Length of Stay | 6 | 2018 | 1126 | 0.350 |
Why?
| | Thoracic Surgical Procedures | 1 | 2010 | 69 | 0.330 |
Why?
| | Retrospective Studies | 17 | 2020 | 14546 | 0.330 |
Why?
| | Catheterization, Central Venous | 1 | 2011 | 97 | 0.330 |
Why?
| | Seizures | 1 | 2013 | 395 | 0.330 |
Why?
| | Heart Rate | 1 | 2013 | 807 | 0.330 |
Why?
| | Abnormalities, Multiple | 1 | 2011 | 178 | 0.320 |
Why?
| | Heparin | 1 | 2011 | 252 | 0.320 |
Why?
| | Gastrostomy | 2 | 2020 | 113 | 0.320 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2012 | 281 | 0.320 |
Why?
| | Lymphoma, Non-Hodgkin | 3 | 2015 | 78 | 0.300 |
Why?
| | Palliative Care | 1 | 2015 | 712 | 0.300 |
Why?
| | Vasculitis | 1 | 2008 | 68 | 0.300 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 4 | 2013 | 85 | 0.290 |
Why?
| | Sepsis | 1 | 2013 | 561 | 0.280 |
Why?
| | Humans | 40 | 2022 | 128896 | 0.270 |
Why?
| | Bortezomib | 6 | 2022 | 44 | 0.260 |
Why?
| | Colorado | 5 | 2020 | 4443 | 0.260 |
Why?
| | Male | 30 | 2020 | 63146 | 0.260 |
Why?
| | Critical Care | 1 | 2011 | 547 | 0.260 |
Why?
| | Respiration, Artificial | 3 | 2020 | 594 | 0.250 |
Why?
| | Female | 29 | 2020 | 68162 | 0.240 |
Why?
| | Incidence | 5 | 2020 | 2634 | 0.230 |
Why?
| | Enterocolitis, Necrotizing | 2 | 2018 | 35 | 0.220 |
Why?
| | Intubation, Intratracheal | 2 | 2020 | 241 | 0.220 |
Why?
| | Biomarkers | 3 | 2016 | 3874 | 0.220 |
Why?
| | Follow-Up Studies | 7 | 2020 | 4917 | 0.220 |
Why?
| | Intubation, Gastrointestinal | 2 | 2020 | 76 | 0.210 |
Why?
| | Child, Preschool | 11 | 2019 | 10457 | 0.200 |
Why?
| | Maintenance Chemotherapy | 1 | 2022 | 22 | 0.200 |
Why?
| | Cohort Studies | 5 | 2019 | 5394 | 0.200 |
Why?
| | Acute Kidney Injury | 4 | 2020 | 786 | 0.200 |
Why?
| | Disease-Free Survival | 5 | 2022 | 657 | 0.190 |
Why?
| | Prospective Studies | 6 | 2018 | 7060 | 0.190 |
Why?
| | Cyclophosphamide | 5 | 2020 | 232 | 0.190 |
Why?
| | Child | 11 | 2020 | 20824 | 0.180 |
Why?
| | Drug Administration Schedule | 6 | 2014 | 760 | 0.180 |
Why?
| | Risk Factors | 8 | 2020 | 9792 | 0.180 |
Why?
| | Cyanosis | 1 | 2020 | 16 | 0.180 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2020 | 5 | 0.180 |
Why?
| | Fundoplication | 1 | 2020 | 54 | 0.170 |
Why?
| | Analysis of Variance | 2 | 2013 | 1283 | 0.170 |
Why?
| | Rituximab | 5 | 2015 | 161 | 0.170 |
Why?
| | Time Factors | 6 | 2013 | 6568 | 0.170 |
Why?
| | Treatment Outcome | 10 | 2020 | 10239 | 0.160 |
Why?
| | Calcaneus | 1 | 2019 | 67 | 0.160 |
Why?
| | Ketorolac | 1 | 2018 | 18 | 0.150 |
Why?
| | Platelet Aggregation | 1 | 2018 | 94 | 0.150 |
Why?
| | Gastroesophageal Reflux | 1 | 2020 | 240 | 0.140 |
Why?
| | Catheters, Indwelling | 1 | 2018 | 79 | 0.140 |
Why?
| | Combined Modality Therapy | 2 | 2010 | 1213 | 0.140 |
Why?
| | Morphine | 1 | 2018 | 128 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2014 | 1968 | 0.130 |
Why?
| | Diuretics | 1 | 2016 | 74 | 0.130 |
Why?
| | Pain, Postoperative | 1 | 2018 | 227 | 0.130 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2016 | 48 | 0.130 |
Why?
| | Sodium | 1 | 2016 | 203 | 0.130 |
Why?
| | Lymphoma, Follicular | 2 | 2015 | 38 | 0.120 |
Why?
| | Bone Density | 1 | 2019 | 470 | 0.120 |
Why?
| | Prognosis | 5 | 2018 | 3787 | 0.120 |
Why?
| | Logistic Models | 4 | 2014 | 1963 | 0.120 |
Why?
| | Gestational Age | 2 | 2020 | 857 | 0.120 |
Why?
| | Hypertension, Pulmonary | 1 | 2005 | 1876 | 0.110 |
Why?
| | Heart | 1 | 2018 | 650 | 0.110 |
Why?
| | Remission Induction | 2 | 2014 | 269 | 0.110 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2013 | 38 | 0.110 |
Why?
| | Port-Wine Stain | 1 | 2013 | 2 | 0.110 |
Why?
| | Delivery Rooms | 1 | 2013 | 7 | 0.110 |
Why?
| | Liver Function Tests | 1 | 2013 | 110 | 0.100 |
Why?
| | Pediatrics | 2 | 2011 | 1060 | 0.100 |
Why?
| | Administration, Topical | 1 | 2013 | 148 | 0.100 |
Why?
| | Lung | 1 | 2005 | 3925 | 0.100 |
Why?
| | Equipment Failure | 1 | 2013 | 112 | 0.100 |
Why?
| | Intubation | 1 | 2012 | 3 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2013 | 424 | 0.100 |
Why?
| | Health Care Surveys | 2 | 2011 | 560 | 0.100 |
Why?
| | Respiration | 1 | 2013 | 191 | 0.100 |
Why?
| | Australia | 1 | 2013 | 247 | 0.100 |
Why?
| | Pentobarbital | 1 | 2011 | 16 | 0.100 |
Why?
| | Survival Rate | 2 | 2013 | 1884 | 0.100 |
Why?
| | Patient Admission | 1 | 2013 | 185 | 0.100 |
Why?
| | Down Syndrome | 1 | 2018 | 454 | 0.100 |
Why?
| | Vein of Galen Malformations | 1 | 2011 | 3 | 0.090 |
Why?
| | Status Epilepticus | 1 | 2011 | 42 | 0.090 |
Why?
| | Hematopoietic Stem Cell Mobilization | 1 | 2011 | 21 | 0.090 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2011 | 21 | 0.090 |
Why?
| | Heterocyclic Compounds | 1 | 2011 | 19 | 0.090 |
Why?
| | Airway Obstruction | 1 | 2013 | 157 | 0.090 |
Why?
| | Professional Practice | 1 | 2011 | 65 | 0.090 |
Why?
| | Receptors, CXCR4 | 1 | 2011 | 82 | 0.090 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 596 | 0.090 |
Why?
| | Linear Models | 1 | 2013 | 817 | 0.090 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2011 | 52 | 0.090 |
Why?
| | Lymphoma, B-Cell | 1 | 2012 | 102 | 0.090 |
Why?
| | Chemoprevention | 1 | 2011 | 88 | 0.090 |
Why?
| | Nutritional Support | 1 | 2010 | 31 | 0.090 |
Why?
| | Anesthetics, Intravenous | 1 | 2010 | 39 | 0.090 |
Why?
| | Ventilator Weaning | 1 | 2010 | 35 | 0.090 |
Why?
| | ROC Curve | 1 | 2012 | 500 | 0.090 |
Why?
| | Diet, Fat-Restricted | 1 | 2010 | 79 | 0.090 |
Why?
| | Electrocardiography | 1 | 2013 | 602 | 0.090 |
Why?
| | Hypnotics and Sedatives | 1 | 2011 | 158 | 0.090 |
Why?
| | Thalidomide | 1 | 2010 | 30 | 0.090 |
Why?
| | Fatal Outcome | 1 | 2011 | 301 | 0.090 |
Why?
| | Analgesics, Opioid | 1 | 2018 | 914 | 0.090 |
Why?
| | Salvage Therapy | 1 | 2011 | 136 | 0.090 |
Why?
| | Propofol | 1 | 2010 | 55 | 0.090 |
Why?
| | Aortic Coarctation | 1 | 2011 | 82 | 0.080 |
Why?
| | Lymphoma | 1 | 2011 | 190 | 0.080 |
Why?
| | Infusions, Intravenous | 3 | 2018 | 395 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 381 | 0.080 |
Why?
| | Drainage | 1 | 2010 | 162 | 0.080 |
Why?
| | Kinetics | 1 | 2013 | 1619 | 0.080 |
Why?
| | Birth Weight | 1 | 2013 | 493 | 0.080 |
Why?
| | Device Removal | 1 | 2010 | 140 | 0.080 |
Why?
| | Plasmapheresis | 1 | 2008 | 23 | 0.080 |
Why?
| | Alprostadil | 1 | 2008 | 32 | 0.080 |
Why?
| | High-Frequency Ventilation | 1 | 2008 | 45 | 0.080 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2014 | 952 | 0.080 |
Why?
| | Diagnosis, Differential | 1 | 2013 | 1435 | 0.080 |
Why?
| | Kidney | 1 | 2016 | 1330 | 0.080 |
Why?
| | Vincristine | 3 | 2015 | 109 | 0.080 |
Why?
| | Renal Replacement Therapy | 1 | 2008 | 88 | 0.080 |
Why?
| | Antibodies, Monoclonal | 2 | 2020 | 1359 | 0.070 |
Why?
| | Neoadjuvant Therapy | 1 | 2010 | 383 | 0.070 |
Why?
| | Adolescent | 8 | 2018 | 20197 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 750 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2015 | 861 | 0.070 |
Why?
| | Doxorubicin | 3 | 2015 | 319 | 0.070 |
Why?
| | Adult | 9 | 2022 | 35361 | 0.070 |
Why?
| | Aged | 7 | 2020 | 22035 | 0.070 |
Why?
| | Transplantation, Autologous | 2 | 2022 | 214 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2012 | 1967 | 0.070 |
Why?
| | Patient Readmission | 1 | 2012 | 674 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2010 | 715 | 0.070 |
Why?
| | Immunologic Factors | 1 | 2008 | 227 | 0.070 |
Why?
| | Preoperative Care | 1 | 2008 | 343 | 0.070 |
Why?
| | Anticoagulants | 1 | 2011 | 622 | 0.070 |
Why?
| | Middle Aged | 8 | 2020 | 30977 | 0.060 |
Why?
| | rho-Associated Kinases | 1 | 2005 | 83 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 525 | 0.060 |
Why?
| | HIV Infections | 1 | 2019 | 2696 | 0.060 |
Why?
| | Immunosuppressive Agents | 1 | 2008 | 699 | 0.060 |
Why?
| | Hemorrhage | 1 | 2008 | 658 | 0.060 |
Why?
| | Attitude of Health Personnel | 1 | 2011 | 1090 | 0.050 |
Why?
| | Maximum Tolerated Dose | 2 | 2014 | 195 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2005 | 420 | 0.050 |
Why?
| | Prednisone | 2 | 2015 | 241 | 0.050 |
Why?
| | Melphalan | 1 | 2022 | 30 | 0.050 |
Why?
| | Thrombocytopenia | 2 | 2015 | 187 | 0.050 |
Why?
| | Lung Diseases | 1 | 2008 | 755 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2019 | 3334 | 0.050 |
Why?
| | Severity of Illness Index | 1 | 2008 | 2767 | 0.040 |
Why?
| | Viscera | 1 | 2020 | 16 | 0.040 |
Why?
| | Immunoglobulin Light Chains | 1 | 2020 | 39 | 0.040 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2020 | 80 | 0.040 |
Why?
| | Cellulitis | 1 | 2020 | 49 | 0.040 |
Why?
| | Nervous System | 1 | 2020 | 65 | 0.040 |
Why?
| | South Africa | 1 | 2019 | 191 | 0.040 |
Why?
| | Heart Failure | 1 | 2012 | 2142 | 0.040 |
Why?
| | Cardiopulmonary Bypass | 1 | 2020 | 193 | 0.040 |
Why?
| | Postoperative Period | 1 | 2018 | 319 | 0.040 |
Why?
| | Thrombelastography | 1 | 2018 | 148 | 0.040 |
Why?
| | Infant Mortality | 1 | 2018 | 97 | 0.040 |
Why?
| | Anti-Retroviral Agents | 1 | 2019 | 229 | 0.030 |
Why?
| | Rats | 1 | 2005 | 5236 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1542 | 0.030 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 339 | 0.030 |
Why?
| | Ultrasonography | 1 | 2019 | 727 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2603 | 0.030 |
Why?
| | Pneumonia | 1 | 2020 | 612 | 0.030 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2015 | 126 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2014 | 88 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 197 | 0.030 |
Why?
| | Hyperbilirubinemia | 1 | 2013 | 11 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2668 | 0.020 |
Why?
| | Neutropenia | 1 | 2013 | 135 | 0.020 |
Why?
| | Liver Failure | 1 | 2013 | 90 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 783 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2011 | 28 | 0.020 |
Why?
| | Ventricular Function, Right | 1 | 2014 | 274 | 0.020 |
Why?
| | Neural Conduction | 1 | 2012 | 82 | 0.020 |
Why?
| | Cytarabine | 1 | 2011 | 54 | 0.020 |
Why?
| | Multiple Organ Failure | 1 | 2012 | 122 | 0.020 |
Why?
| | Indoles | 1 | 2014 | 378 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2011 | 113 | 0.020 |
Why?
| | Benzylamines | 1 | 2011 | 42 | 0.020 |
Why?
| | Prostaglandins | 1 | 2011 | 85 | 0.020 |
Why?
| | Survival Analysis | 1 | 2014 | 1282 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2038 | 0.020 |
Why?
| | Mouth | 1 | 2011 | 81 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2011 | 91 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2011 | 72 | 0.020 |
Why?
| | Blood Component Removal | 1 | 2011 | 25 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3286 | 0.020 |
Why?
| | Liver Cirrhosis | 1 | 2013 | 274 | 0.020 |
Why?
| | Internationality | 1 | 2011 | 148 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2014 | 1858 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 1013 | 0.020 |
Why?
| | Electroencephalography | 1 | 2011 | 387 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 7050 | 0.020 |
Why?
| | Animals | 2 | 2010 | 34628 | 0.020 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 378 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2011 | 615 | 0.020 |
Why?
| | Hospital Mortality | 1 | 2012 | 853 | 0.020 |
Why?
| | Internet | 1 | 2011 | 616 | 0.020 |
Why?
| | Young Adult | 2 | 2011 | 12286 | 0.010 |
Why?
| | Liver | 1 | 2013 | 1832 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 5270 | 0.010 |
Why?
| | United States | 1 | 2011 | 13975 | 0.010 |
Why?
| | Mice | 1 | 2010 | 16543 | 0.010 |
Why?
|
|
Kaufman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|